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Abstract
Background—The human papillomavirus (HPV) test, administered alone without the 
Papanicolaou (Pap) test, was recently recognized as a cervical cancer screening option in the 
United States by the Society of Gynecologic Oncology and the American Society for Colposcopy 
and Cervical Pathology, and the Food and Drug Administration has approved an HPV test for 
primary screening.
Methods—Surveys of US internists, family practitioners, nurse practitioners, and obstetrician–
gynecologists were conducted in 2009 and 2012 to investigate providers’ perceptions of the 
effectiveness of the HPV test administered alone as a population-based screening modality (2009: 
N = 1040, 141–494 per provider group; 2012: N = 1039, 155–435 per provider group).).
Results—The majority in each provider group agreed that the HPV test administered alone is an 
effective screening modality in 2009 (75.3%–86.1%) and 2012 (79.5%–91.8%), and agreement 
rose significantly during this time period among family practitioners (χ2 = 15.26, df = 1, p < 
0.001) and nurse practitioners (χ2 = 4.53, df = 1, p = 0.033).
Conclusions—Agreement that the HPV test administered alone is an effective cervical cancer 
screening modality was widespread among providers in both 2009 and 2012, however 
implementation of guidelines for screening with the HPV test may be influenced by many other 
factors including reimbursement and patient preferences.
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Currently two cervical cancer screening strategies are recommended by the American 
Cancer Society (ACS) (Saslow et al., 2012), American College of Obstetricians and 
Gynecologists (ACOG) (2012), and US Preventive Services Task Force (USPSTF) (2012): 
1) Papanicolaou (Pap) testing every 3 years for women aged 21–65 years and 2) Pap testing 
every 3 years for women aged 21–29 years followed by testing with both the Pap test and 
the human papillomavirus (HPV) test (also known as co-testing) administered every 5 years 
for women aged 30–65 years. Similarly, Pap testing and co-testing are the only cervical 
cancer screening modalities included in HEDIS measures, which are used by 90% of US 
health plans to assess care quality (National Committee for Quality Assurance).
However, the HPV test, administered alone without the Pap test, was recently recognized as 
a cervical cancer screening option. The US Food and Drug Administration (FDA) approved 
an HPV test for primary screening in 2014, and the Society of Gynecologic Oncology 
(SGO) and the American Society for Colposcopy and Cervical Pathology (ASCCP) released 
interim guidelines which endorsed screening with the HPV test alone every 3 years for 
women aged 25 years and older in 2015 (Huh et al., 2015). While the Pap test detects the 
presence of precancerous cells on the cervix, the HPV test detects a prevalent oncogenic 
HPV infection. Like a positive Pap test, a positive HPV test requires followup testing to 
confirm a diagnosis of precancer or cancer.
We investigated US providers’ perceptions of the effectiveness of the HPV test administered 
alone as a primary screening modality in 2009 and 2012, which predated FDA approval of a 
specific test for this indication and the release of the SGO/ASCCP interim guidelines. The 
current ACS (Saslow et al., 2012), ACOG (American College of Obstetricians and 
Gynecologists, 2012), and USPSTF (US Preventive Services Task Force, 2012) screening 
recommendations were issued shortly before the 2012 survey. At the time of the 2009 
survey, ACS (Saslow et al., 2002) and ACOG (A.C.O.G. Committee on Practice Bulletins, 
2003) guidelines included co-testing as a recommended screening modality when 
administered every 3 years among low-risk women aged 30 years and older with previous 
negative tests, but the USPSTF (US Preventive Services Task Force, 2003) did not 
recommend co-testing at that time.
Methods
Data from the 2009 and 2012 DocStyles surveys of US health care providers were analyzed. 
The surveys were administered online by Porter Novelli (Washington DC) in July 2009 and 
July 2012. Participants were recruited from the Epocrates Honors Panel, which includes 
more than 275,000 US health professionals. The opportunity to join the panel and be a paid 
research participant was offered when providers registered for Epocrates®, the leading 
medical reference app in the United States (Epocrates) with >1,000,000 users (Epocrates). 
At the time of panel enrollment, the identities of physicians were verified by comparing first 
name, last name, date of birth, medical school, and graduation date against the American 
Medical Association’s (AMA) Masterfile®, an inventory of licensed US physicians that 
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includes both AMA members and non-members. However, no verification of the identities 
of nurse practitioners was performed.
The 2009 and 2012 survey participants were limited to providers who actively saw patients 
and had practiced for at least 3 years. A variety of provider groups were studied, but the 
analyses reported here included only internists, family practitioners, nurse practitioners, and 
obstetrician–gynecologists.
An invitation to participate in the surveys was emailed to randomly selected primary care 
physicians (internists and family practitioners; 2325 in 2009 and 2175 in 2012), nurse 
practitioners (500 in 2009 and 456 in 2012), and obstetrician–gynecologists (500 in 2009 
and 489 in 2012). The samples of physicians matched the 2009 and 2012 American Medical 
Association Masterfile estimates for age, gender, and geographic region. The samples of 
nurse practitioners were randomly drawn, but not selected to match any demographic 
thresholds. Quota sampling (Cumming, 1990) was used to ensure adequate representation of 
all provider groups surveyed. In both 2009 and 2012, the quotas were 1000 primary care 
physicians, 250 nurse practitioners, and 250 obstetrician–gynecologists, and these quotas 
were filled or slightly exceeded in two instances—the 2012 sample included 1001 primary 
care physicians and 252 nurse practitioners, as a result of multiple providers responding 
simultaneously. Primary care physicians who took part in the surveys included 391 internists 
and 609 family practitioners in 2009 and 464 internists and 537 family practitioners in 2012, 
and these specialties were analyzed separately. Analyses in the present study were limited to 
providers who performed ≥1 Pap test per month and worked primarily in out-patient settings 
which narrowed the 2009 sample to 189 internists, 494 family practitioners, 141 nurse 
practitioners, and 216 obstetrician–gynecologists and the 2012 sample to 205 internists, 435 
family practitioners, 155 nurse practitioners, and 244 obstetrician–gynecologists.
The 2009 and 2012 survey respondents were paid $20–$95 depending on specialty. The 
surveys were administered by Porter Novelli and complied with the ICC/ESOMAR 
International Code for ethical research (ESOMAR, 2008). The survey items analyzed in the 
present study were licensed by CDC’s Inside Knowledge: Get the Facts About Gynecologic 
Cancer campaign (www.cdc.gov/cancer/knowledge), in order to inform efforts to increase 
gynecologic cancer awareness. This project was not subject to CDC IRB review as it 
involved secondary data analysis, and no individual identifiers were included in the dataset 
received by investigators.
In both the 2009 and 2012 surveys, the perceived effectiveness of cervical cancer screening 
options was assessed by asking providers if the Pap test (cytology) alone, co-testing (Pap 
test in conjunction with the HPV test), and the HPV test alone were “effective cervical 
cancer screening modalities for asymptomatic women in the average-risk population.” 
Cervical cancer screening practices were only assessed in the 2012 survey; providers were 
asked what cervical cancer screening modality they typically used with asymptomatic 
women aged 30–65 years with four response options provided: Pap test (cytology) alone, co-
testing (Pap test in conjunction with the HPV test), either the Pap test alone or co-testing 
depending on patient preference, and other (use of HPV testing alone was not assessed, as 
this screening modality was not recommended at the time of the study). Providers in 2012 
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who indicated that they typically used co-testing or provided it based on patient preference 
were asked what co-testing interval they generally recommended for asymptomatic women 
aged 30–65 years with five response options provided: annually, every 2 years, every 3 
years, every 5 years, and other.
To assess the comparability of the 2009 and 2012 samples, provider characteristics were 
compared by year within each provider group using Pearson chi square tests (categorical 
variables) and t-tests (continuous variables). In addition, Pearson chi square tests were used 
to compare perceived effectiveness of screening options 1) among provider groups in 2009, 
2) among provider groups in 2012, and 3) by year within each provider group.
Results
The 2009 and 2012 samples were generally comparable with three exceptions—the 2012 
sample included a significantly higher percentage of female family practitioners, and the 
mean ages of internists and obstetrician–gynecologists were significantly higher than the 
2009 sample (Table 1). Agreement that Pap testing and co-testing are effective screening 
strategies was consistently high (≥90%) in 2009 and 2012 across all provider groups 
surveyed. The majority (N70%) in each provider group in 2009 and 2012 also agreed that 
the HPV test alone is an effective screening modality (Fig. 1), and agreement rose 
significantly during this time period among family practitioners and nurse practitioners. In 
2009 and 2012, agreement about test effectiveness was highest among obstetrician–
gynecologists and lowest among internists for co-testing (2009: χ2 = 15.12, df = 3, p = 
0.002, 2012: χ2 = 9.90, df = 3, p = 0.019) and HPV testing (2009: χ) and HPV testing (2009: 
χ2 = 13.71, df = 3, p = 0.003, 2012: χ2 = 15.61, df = 3, p = 0.001) (results not shown). 
However, no difference in agreement about the effectiveness of Pap testing was found 
between provider groups in 2009 or 2012.) (results not shown). However, no difference in 
agreement about the effectiveness of Pap testing was found between provider groups in 2009 
or 2012.
In 2012, the majority (N58%) in all provider groups reported that they typically screened 
women aged 30–65 years using co-testing. A 3-year co-testing interval was used most 
commonly (39.5%–55.3% depending on specialty), and a 5-year co-testing interval was used 
least often (5.5%–7.0%).
Discussion
Our findings provide evidence of widespread and growing acceptance of the HPV test as a 
stand-alone screening modality. This increasing acceptance predated FDA approval of an 
HPV test for primary screening (US Food and Drug Administration) and the release of the 
SGO/ASCCP interim guidelines endorsing the HPV test administered alone as a screening 
modality (Huh et al., 2015). The 2009 results are especially surprising, as no screening 
options involving the HPV test was recommended by the USPSTF (US Preventive Services 
Task Force, 2003) at that time (although, ACS (Saslow et al., 2002) and ACOG (A.C.O.G. 
Committee on Practice Bulletins, 2003) endorsed co-testing in 2002).
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In both 2009 and 2012, the perceived effectiveness of the HPV test administered alone and 
co-testing was highest among obstetrician–gynecologists and lowest among internists. This 
pattern may reflect the volume of cervical cancer screening administered with providers who 
screen larger numbers of women being more familiar with HPV-related research and 
guidelines. It is also possible that internists, family practitioners, and nurse practitioners may 
be more familiar with the USPSTF (US Preventive Services Task Force, 2012) guidelines, 
which recommended co-testing more recently than ACOG (American College of 
Obstetricians and Gynecologists, 2012), as previously noted.
Co-testing was the most widely used screening modality across all provider groups in 2012, 
but, few providers (5.5%–7.0% depending on specialty) reported using the recommended 5-
year co-testing interval. It should be reiterated that current screening recommendations 
(Saslow et al., 2012; American College of Obstetricians and Gynecologists, 2012; US 
Preventive Services Task Force, 2012) were issued shortly before the 2012 survey, and 
respondents may have lacked familiarity with them and specifically, the new 5-year 
screening intervals. Cotesting was associated with similar levels of perceived effectiveness 
as Pap testing (co-testing = 90.7%–97.1; Pap testing = 95.6%–97.5%). However, screening 
intervals were not specified in perceived effectiveness measures.
No comparison data for the results reported here were identified, and the use of quota 
sampling (Cumming, 1990) limits generalizability. However, physicians who participated in 
the 2009 and 2012 DocStyles surveys were found to be comparable with providers in the 
same specialty in the corresponding years of the AMA Masterfile in terms of gender, 
average age, and geographic region (Porter Novelli, 2009, and 2012).
Implementation of US guidelines for primary screening with the HPV test may not be as 
rapid as the present study suggests. Providers’ acceptance of any specific parameters for 
primary screening with the HPV test was not assessed. The new SGO/ASCCP interim 
guidelines endorse a 3-year screening interval for the HPV test administered alone to women 
aged 25 years and older (Huh et al., 2015). However, there is evidence which supports the 
effectiveness of longer screening intervals (Dillner et al., 2008; Elfström et al., 2014), and 
Australia’s National Cervical Screening Program recently adopted HPV testing every 5 
years for women aged 25 to 74 years old (Services Advisory Committee and Standing 
Committee on Screening). While a 3-year co-testing interval was the most widely used in 
the current study, providers may be less comfortable with screening every 3 years or longer 
when the HPV test is administered without the Pap test. Similarly, providers may not 
support the age threshold of 25 years for primary screening with the HPV test (Sawaya and 
Kuppermann, 2015), as the HPV infection is prevalent among women aged 25–29 years 
(Dunne et al., 2007) and often regresses without intervention (Ault, 2006). Further, cervical 
cancer is uncommon among women younger than 30 years old (Benard et al., 2012). Thus, 
providers may believe that the possibility of unnecessary treatment and associated harms 
outweighs any benefit of diagnosing the HPV infection among women in their twenties 
(Sawaya and Kuppermann, 2015).
Many other factors, in addition to providers’ perception of test effectiveness, can influence 
cervical cancer screening practices including standards of care encouraged by health 
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maintenance organizations and other payors (Sarfaty and Myers, 2008), reimbursement 
(Halpern et al., 2014), and patient preferences (Teoh et al., 2015), which may be especially 
relevant in this instance (resistance to the HPV test as a stand-alone screening modality has 
been detected among US women (Silver et al., 2015). Of course, patient acceptance of 
screening guidelines can depend largely on provider recommendations (Finney Rutten et al., 
2004), and the extent to which providers will embrace primary screening with the HPV test 
administered alone remains to be seen.
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Agreement that cervical cancer screening options involving the human papillomavirus 
(HPV) test are effective by year and specialty, US providers, 2009 and 2012 DocStyles 
surveys.
Note: Analyses were limited to providers who worked in out-patient settings and performed 
≥1 Pap test per month.
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